SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2004-05-18** | Period of Report: **2004-05-18** | SEC Accession No. 0000914317-04-002092

(HTML Version on secdatabase.com)

FILER

VASOGEN INC

CIK:1042018| IRS No.: 9999999999 | Fiscal Year End: 1130 Type: 6-K | Act: 34 | File No.: 000-29350 | Film No.: 04814966 SIC: 3841 Surgical & medical instruments & apparatus Mailing Address 2155 DUNWIN DR SUITE 10 L5L4M1 MISSISSAUGA ONTARIO Business Address 2155 DUNVIN DR SUITE 10 L5L4M1 MISSISSAUGA ONTARIO A6 00000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the month of May 2004

Commission File Number: 0-29350

Vasogen Inc. (Translation of registrant's name into English)

2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1). _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): $___$

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information

contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12q3-2 (b): 82-

On May 17, 2004, Vasogen Inc. issued a press release "Vasogen Added to NASDAQ Biotechnology Index". The press release announcing the addition of Vasogen to the NASDAQ Biotechnology Index is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VASOGEN INC.

By: /s/ Christopher Waddick

Name: Christopher Waddick

Title: Executive Vice President and Chief Financial

Officer

Date: May 17, 2004

Exhibit List

Exhibit Description

99.1 Press release of Vasogen Inc. dated May 17, 2004

Vasogen Inc.

Contact:

Glenn Neumann, Investor Relations 2155 Dunwin Drive Mississauga, ON, Canada L5L 4M1

tel: (905) 569-9065 fax: (905) 569-9231 www.vasogen.com / investor@vasogen.com

FOR IMMEDIATE RELEASE

Vasogen Added to NASDAQ Biotechnology Index

Mississauga, Ontario (May 17, 2004) -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a research and development company focused on immune modulation therapies targeting the chronic inflammation underlying cardiovascular and neurological disorders, today announced that it has been selected to be added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective with the market open on Monday, May 24, 2004.

All securities in the Index are listed on the NASDAQ National Market and must be classified according to the FTSE Global Classification System as either biotechnology or pharmaceutical. In addition, all securities in the Index must meet minimum requirements for market value, average daily share volume, and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November.

About Vasogen:

Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Vasogen's lead product, Celacade(TM) (immune modulation therapy) is currently in phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. Celacade(TM) is designed to target chronic inflammation by activating the immune system's physiological anti-inflammatory response to apoptotic cells. Celacade(TM) up-regulates the expression of cell surface molecules that interact with specific receptors on antigen presenting cells (APCs) to modulate the production of cytokines - potent chemical messengers that initiate and control inflammation. Vasogen is also developing a new class of phospholipid-based drugs, which includes VPO25, designed to interact with APCs to regulate cytokine levels and control inflammation.

This press release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking

statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," "plans," "intends," "will," "should," "expects," "projects," and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.